small molecule

NUPLAZID

PIMAVANSERIN TARTRATE

Loss of exclusivityFebruary 2039latest FDA-listed patent expiry

CompanyAcadia Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	NUPLAZID
Active ingredient	PIMAVANSERIN TARTRATE
Strength	EQ 34MG BASE
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	June 2018
Marketing status	RX

Listed patents

Patent	Expires	Type
10646480*PED	February 2039	—
11452721*PED	February 2039	—
10849891*PED	February 2039	—
10449185*PED	February 2039	—
10646480	August 2038	product
10849891	August 2038	product
11452721	August 2038	product
10449185	August 2038	product
7601740*PED	October 2030	—
7601740	April 2030	substance, product
7732615*PED	December 2028	—
7732615	June 2028	substance, product
7659285	August 2026	use U-1844

Regulatory exclusivity

Code	Expires
PED	October 2029
M-14	April 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Acadia Pharmaceuticals